SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists have emerged alongside RAS inhibitors as the four main pillars of treatment for diabetic kidney disease.
従来，糖尿病性腎症の治療薬はras阻害薬のみであったが，sglt2阻害薬の登場によって大きな変革がもたらされた．近年，sglt2阻害薬に加え，非ステロイド型mr拮抗薬であるフィネレノンそしてglp-1受容体作動薬であるセマグルチドの腎症抑制のエビデンスが明らかとなり，注目されている．これら4本の治療の柱が糖尿病性腎症の治療薬として中心的役割を担うことが期待される．
Daiji Kawanami (Thu,) conducted a review in Diabetic kidney disease. SGLT2 inhibitors, non-steroidal MR antagonists, and GLP-1 receptor agonists was evaluated. SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists have emerged alongside RAS inhibitors as the four main pillars of treatment for diabetic kidney disease.